Prostate cancer
Conditions
Interventions
Case series:adjuvant therapy combine with androgen suppression and docetaxel
Sponsors
The First Affiliated Hospital of Zhejiang University
Eligibility
Sex/Gender
Male
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged=80 years; 2. ECOG=1 and life expectance more than 10 years . 3. Pathologically proven diagnosis of adenocarcinoma of the prostate gland at the time of prior radical prostatectomy meeting one of the following combinations: (1) Pathologic Gleason = 8 and = pT3b classification; (2) Pelvic lymph node metastases and any pT classification; (3) pT4 classification. 4. Enrollment must occur within 3 months from radical prostatectomy; 5. There are some important things (1) Hemoglobin = 9.0 g/dl; (2) Absolute neutrophil count (ANC) = 1,500 cells/mm3; (3) Platelets = 100,000 cells/mm3; (4) Serum potassium =3.5mmol/L; (5) ALT, AST= 1.5x institutional upper normal limits; total bilirubin =1.5x institutional upper normal limits; (6) Serum albumin =30g/L; 6. Patient must provide study-specific informed consent prior to study entry.
Exclusion criteria
Exclusion criteria: 1. Bone metastate, liver,brain or other viscera metastate by radiological evidence; 2. Prior invasive malignancy or prior systemic chemotherapy or biological therapy for the prostate cancer; 3. Severe, active co-morbidity, defined as follows: Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months; Transmural myocardial infarction within the last 6 months;Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration;Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration; virus hepatitis or chronic hepatic disease;Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; 4. Prior allergic reaction to the study drug(s) involved in this protocol; 5. Patient participated in other drug clinical trial within one month prior to the first use of chemotherapy,.(If the previous drug had a long half-life, there would be at least five times as much washout time before the first study was used as the previous study.)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PSA; | — |
Secondary
| Measure | Time frame |
|---|---|
| imageological examination;Bone ECT Scan; | — |
Countries
China
Contacts
Public ContactShuo WANG
The First Affiliated Hospital of Zhejiang University
Outcome results
None listed